Evolus (EOLS) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Evolus (EOLS) do?
Evolus Inc (EOLS) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Sells Jeuveau, an injectable botulinum toxin type A designed specifically for aesthetic facial treatments. Evolus focuses exclusively on cash-pay aesthetic neurotoxins and dermal fillers sold directly to medical practitioners. It is worth $463.32M on the market and sold $326.28M over the last year.
- Market cap
- $463.32M
- P/E ratio
- None (reported a loss)
- Annual sales
- $326.28M
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Brief updated
- Nov 17, 2026
Brands and businesses behind EOLS
- Jeuveau: It is an injectable aesthetic neurotoxin that earns revenue through direct product sales to licensed medical practitioners.
- Evolysse: It is a line of hyaluronic acid dermal fillers sold directly to aesthetic clinics to generate product revenue.
- Nuceiva: It is the international brand name for Jeuveau, generating export sales across European and Canadian markets.
EOLS’s flags, in plain English
Each flag is a number from Evolus’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Still Climbing
Sales up 39.4% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Wide Gross Margin
Gross margin of 64.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Insiders Hold
Insiders own 12.4% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -9.6%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about EOLS
How big is Evolus?
Evolus’ market cap is $463.32M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $326.28M: what customers paid the company over the last year, before any costs.
What is EOLS’s P/E ratio?
EOLS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with EOLS?
The business relies on a single South Korean contract manufacturer for all supplies of its primary neurotoxin product. That is one risk on Evolus’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Evolus’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. EOLS’s filings on SEC.gov. The Margin Monkey is research, not advice.
